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PrognosisThe alterations in glucose homeostasis in the early phase of nondiabetic ST-elevation myocardial infarction
(STEMI) are complex, involving not only hyperglycemia but also the development of acute insulin resistance
(as part of the stress response) as assessed by the Homeostatic Model Assessment index (HOMA). No data is
so far available on C-peptide values in the acute phase of STEMI in patients without previously known diabetes.
The aims of the present investigation, performed in 782 consecutive STEMI patients without previously known
diabetes, were as follows: a) to assess the determinants of C-peptide levels; b) to address the relation between
acute insulin-resistance and Killip class; and c) to investigate the prognostic role of C-peptide for early mortality.
In our series, 729 patients (93.2%) were in Killip I–II (group A), while 53 patients (6.8%) were in Killip classes III–
IV (groupB). Group B showed higher levels of admission glycemia, insulin andC-peptide (pb 0.001, p= .022 and
p b 0.001 respectively), together with higher values of HOMA-index and log-HOMA (p b 0.001 and p b 0.001,
respectively) and reduced HOMA-%B (p = 0.014). Left ventricular ejection fraction was inversely correlated
with C-peptide, insulin and admission glycemia (p b 0.001, p = 0.018 and p b 0.001, respectively). At logistic
regression analysis C-peptide and insulin values were not associated with in-ICCU death.
According to our data, the development of acute insulin resistance in the early phase of STEMI can be viewed
as an adaptive mechanism to stress (represented by acute myocardial ischemia), similar to other acute critical
conditions, related to the severity of stress (that is to the hemodynamic impairment).
© 2014 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Introduction
In the setting of acutemyocardial infarction [1], hyperglycemia is not
simply a marker of pre-existing diabetes or glucose intolerance but it
may represent a stress response to myocardial injury mainly related to
acute catecholamine release [2,3]. In patients with ST elevationmyocar-
dial infarction (STEMI) several studies addressed the glucose stress
response [4] by investigating the prognostic role of glucose values
measured on admission and throughout hospital stay [5–8].
However, the alterations in glucose homeostasis in the early phase of
STEMI are far more complex, including also the development of acute
insulin resistancewhich has been so far investigated only by few studies
by means of the Homeostatic Model Assessment (HOMA index) [9,10].
No data is so far available on C-peptide values in the acute phase of
STEMI in patients without previously known diabetes, taking into
account that C-peptide is a robust measure of insulin secretion but not
of insulin action [11], differently from HOMA index., Heart and Vessel Department,
7947518.
land Ltd. Open access under CC BY-NCSince in critically ill patients the severity of insulin resistance is
associatedwith the severity of illness [12], we hypothesized that in non-
diabetic STEMI patients advanced Killip classes were associated with a
more severe acute insulin resistance.
The aims of the present investigation, performed in 782 consecutive
STEMI patients without previously known diabetes, were as follows:
a) to assess the determinants of C-peptide levels; b) to address the
relation between acute insulin-resistance and Killip class; and c) to
investigate the prognostic role of C-peptide for early mortality.Methods
From 1st April 2009 to 31st December 2012, 782 consecutive
patients with STEMI (within 12 h from symptoms' onset) and without
previously known diabetes were admitted to our Intensive Cardiac
Care Unit (ICCU), which is located at a tertiary center (where primary
percutaneous coronary intervention-PCI- can be performed 24/24 h
7 days/week). In our hospital, in Florence, the reperfusion strategy of
STEMI patients is represented by primary PCI [13–16]. After primary
PCI, they are admitted to our ICCU.
The diagnosis of STEMI was based on the criteria of the American
College of Cardiology/American Heart Association [13,16].-ND license.
Table 1
Clinical characteristics.
All patients
Age (years), mean ± SD 65.5 ± 13.3
Males/Females, n (%) 578/204
(73.9/26.1)
BMI (Kg/m2), mean ± SD 26.1 ± 3.6
History of, n (%)
Smoking 506 (64.7)
COPD 65 (8.3)
Previous PCI 93 (11.9)
Previous AMI 92 (11.8)
Hypertension 347 (44.4)
Comorbidities, n (%)
0 71 (9.1)
1–2 571 (73.0)
N2 140 (17.9)
Charlson index (units),
mean ± SD 1.0 (1.0–2.0)
1.67±1.26
AMI location, n (%)
anterior 393 (50.3)
inferior 336 (43.0)
Other 53 (6.8)
Coronary artery disease, n (%)
1-vessel 337 (43.1)
2-vessel 278 (35.5)
3-vessel 167 (21.4)
Left main involvement, n (%) 44 (5.6)
PCI failure, n (%) 38 (4.9)
EF (%), mean ± SD 44.5 ± 9.3
Time door-to-balloon (minutes),
median (IR) 210 (150 to 300)
In-hospital mortality, n (%) 21 (2.7)
COPD: chronic obstructive pulmonary disease; PCI: percutaneous coronary intervention;
BMI: body mass index; AMI: acute myocardial infarction; LM: left main coronary artery;
and EF: ejection fraction.
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parameters were measured: glucose (g/l), glycated hemoglobin (%),
insulin (mU/l), C-peptide (mU/l), troponin I (Tn I, ng/ml), uric acid
(mg/dl), NT-pro Brain Natriuretic Peptide (NT-pro BNP) (pg/ml), leuko-
cytes count (∗103/μl), ﬁbrinogen (mg/dl) and hs-C-Reactive protein
positivity (hs-CRP) (normal values b 9). Intensive insulin therapy was
administered in patients with signiﬁcant hyperglycemia (that is plasma
glucose N 180 g/l) [4].
The presence of comorbidities was determined by taking the
patients' history directly and Charlson index was calculated [17].
Indexes of insulin-resistance/sensitivity
Criteria used for the deﬁnition of insulin resistance are in accordance
with the recently published guidelines proposed by the EuropeanGroup
of the study of Insulin Resistance (EGIR) [18]. The Homeostatic Model
Assessment index (HOMA) was calculated according to the following
formula: {[fasting insulin (μU/ml)] × [fasting glucose (mmol/l)]}/
22.5. Subjects whose values exceeded the sex-speciﬁc 75th percentile
(i.e. 1.80 for women and 2.12 for men) were considered to have insulin
resistance (HOMA-IR) [10,18]. Log (HOMA-IR) has been also calculated
since it is considered useful for evaluation of insulin-resistance in
individuals with glucose intolerance, mild to moderate diabetes and
other insulin-resistant conditions [19,20].
Beta-function has been evaluated by the following index [21]:
HOMA-%B = (20 × FPI) / ((FPG-3.5) where FPI is the fasting plasma
insulin and FPG is the fasting plasma glucose [19,21–24].
Transthoracic 2-dimensional echo-cardiography was performed on
ICCU admission in order to measure left ventricular ejection fraction
(LVEF).
The primary outcome was in-ICCU death.
The study protocol was in accordance with the Declaration of
Helsinki and approved by the local Ethics Committee. Informed singed
consent was obtained in all patients before enrollment.
Statistical analysis
Data have been stored in a dedicated data-base and analyzed with
IBM SPSS Statistics 20 for Microsoft® Windows® (SPSS-IBM, USA).
Continuous data are reported as mean ± SD or median (interquartile
range, IR) as needed; comparisons between patients admitted in Killip
classes I–II and III–IV were performed by means of Student's t-test or
Mann–Whitney U-test, respectively. Categorical data are reported as
frequencies (percentages); between-group comparisons were made
with chi-square test. Correlations between some relevant anthropo-
metric, clinic and laboratory data with admission glucose, insulin and
C-peptide have been assessed with Spearman's rho. Logistic multivari-
able regression analysis was used to investigate the impact of age,
peak TnI, glucose, creatinine and C-peptide on in-ICCU death. Candidate
variables were chose as those considered relevant for the outcome,
taking into account the number of events. Nevertheless, both models
resulted slightly overﬁtted. Hosmer–Lemeshow goodness-of-ﬁt test
and Nagelkerke pseudo-R2 were reported for logistic models. Statistical
signiﬁcance has been ﬁxed at a two-tailed p value less than 5%.
Results
Table 1 depicts the clinical characteristics of the overall study popu-
lation. In our series, the incidence of PCI was 4.9%, and in-ICCUmortality
and 1-year discharge mortality rates were 2.7 and 4.2%, respectively. As
shown in Table 2, 729 patients (93.2%) were in Killip I–II, while 53
patients (6.8%) were in Killip classes III–IV. Patients in Group B showed
a higher Charlson index (p b 0.001), more frequently anterior myocar-
dial infarction (p= 0.041) and a 2-and 3-vessel coronary artery disease
(p= 0.017), together with a higher incidence of PCI failure (p b 0.001)
and a lower admission EF (p b 0.001). A higher in-ICCU mortality ratewas observed in Group B (p b 0.001). Higher values of Tn I, creatinine
(admission, peak and discharge), NT-pro BNP, uric acid were observed
inGroup B, togetherwith a higher inﬂammatory activation (as indicated
by increased values of leukocytes and CRP positivity). When compared
to patients in Group A, patients in Group B showed signiﬁcantly higher
levels of admission glycemia, insulin and C-peptide (p b 0.001, p= .022
and p b 0.001 respectively), together with higher values of HOMA-
index and log-HOMA (p b 0.001 and p b 0.001, respectively) and
reduced HOMA-%B (p = 0.014). No difference was observed in HbA1C
values between the two subgroups.
As shown in Table 3, LVEF was inversely correlated with C-peptide,
insulin and admission glycemia (p b 0.001, p= 0.018 and p b 0.001, re-
spectively). Similarly age showed an indirect correlationwith C-peptide,
insulin and admission glycemia (p = 0.011, p = 0.073 and p b 0.001,
respectively).
At logistic regression analysis (Table 4) C-peptide and insulin values
were not associated with in-ICCU death.
Discussion
Homeostasis model assessment (HOMA), developed in 1985 [23], is
a model of interactions between glucose and insulin dynamics that are
used to yield an estimate of insulin sensitivity and beta-cell function
[23]. The HOMA index assumes a feedback loop between the liver and
beta-cell [19–23]; i.e., the relation between glucose and insulin in the
basal state reﬂects the balance between hepatic glucose output and
insulin secretion [19,21]. Thus, deﬁcient beta-cell function reﬂects a
diminished response of beta-cell to glucose-stimulated insulin secre-
tion. While the euglycemic hyperinsulinemic clamp is time consuming,
labor intensive and requires an experienced operator to manage the
technical difﬁculties, HOMA index is feasible in all clinical conditions
and information provided by this test is promptly available for
Table 2
Clinical and laboratory data according to Killip class.
Killip classes I–II
n = 729, 93.2%
Group A
Killip classes III–IV
n = 53, 6.8%
Group B
p value ⁎
t-test,
Mann-Whitney U or χ2
Age (years), mean ± SD 65.2 ± 13.3 68.4 ± 12.6 0.090 t
Males/females, n (%) 544/185
(74.6/25.4)
34/19
(64.2/35.8)
0.094 χ2
BMI (kg/m2), mean ± SD 26.2 ± 3.6 25.4 ± 4.0 0.129 t
Charlson index (units),
mean ± SD
1 (1–2)
1.61 ± 1.22
2 (1–3)
2.47 ± 1.41
b0.001 U
b0.001 t
AMI location, n (%) 0.041 χ2
Anterior 359 (49.2) 34 (64.2)
Inferior 322 (44.2) 14 (26.4)
Other 48 (6.5) 5 (9.4)
Coronary artery disease, n (%) 0.017 χ2
1-Vessel 324 (44.4) 13 (24.5)⁎
2-Vessel 254 (34.8) 24 (45.3)
3-Vessel 151 (20.7) 16 (30.2)
PCI failure, n (%) 33/723 (4.6) 10/53 (18.9) b0.001 χ2
EF (%), mean ± SD 45.4 ± 8.8 34.6 ± 9.8 b0.001 t
Time door-to-balloon (minutes), median (IR) 210 (150–300) 210 (138–289) 0.726 U
In-hospital mortality, n (%) 9 (1.2) 12 (22.6) b0.001 χ2
Laboratory data
Admission Glucose (g/l), median (IR) 1.23 (1.05 to 1.45) 1.62 (1.25 to 2.05) b0.001 U
Insulin values (mU/l), median (IR) 8.7 (5.3 to 14.6) 12.4 (5.1 to 30.6) 0.022 U
C-peptide values (mU/l), median (IR) 0.94 (0.64 to 1.27) 1.32 (0.88 to 2.26) b0.001 U
HOMA index, median (IR) 0.47 (0.27 to 0.88) 0.83 (0.34 to 2.74) b0.001 U
Log HOMA −0.21 ± 0.46 0.10 ± 0.54 b0.001
HOMA-%B (insulin) 54.2 (33.9–80.6) 39.0 (20.9–77.9) 0.014
HbA1c N 6.5%, n (%) 63 (8.6) 6 (11.3) 0.725 χ2
Tn I (ng/ml), median (IR) 79.2 (35.8–156.0) 221.0 (95.5–426.9) b0.001 U
Admission creatinine, median (IR) 0.90 (0.73–1.00) 1.10 (0.90–1.40) b0.001 U
NT-proBNP (pg/ml) (n = 575), median (IR) 1079 (404–2508) 2620 (1279–11665) b0.001 U
Uric acid (mg/dl) (n = 668), mean ± SD 5.6 ± 1.6 6.3 ± 243 0.038 t
ESR (mm/h) (n = 708), median (IR) 20 (10–35) 26 (15–42) 0.097 U
Leucocytes (1000 counts/μl), median (IR) 10.5 (8.5–13.1) 13.3 (10.0–19.2) b0.001 U
CRP positivity (%), n (%) 351(48.2) 38 (71.6) 0.008 χ2
Fibrinogen (mg/dl), mean ± SD 409 ± 107 410 ± 126 0.983 t
MI: acute myocardial infarction, HOMA: Homeostatic Model Assessment; BMI: body mass index; EF: ejection fraction; PCI: percutaneous coronary intervention; NT-pro-BNP: N terminal
pro Brain Natriuretic Peptide; ESR: erythrocyte sedimentation rate; and CRP: C-Reactive Protein;
⁎ t: at Student's t-test; χ2: at chi-square test; U: at Mann–Whitney U-test.
Table 4
Logistic regression analysis.
Adjusted OR 95% CI p value
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tance in critically ill patients with acute renal failure [25] as well as in
critically ill medical patients [26,27] and we recently [10] documented
that, in the acute phase of STEMI, HOMA index represented an indepen-
dent predictor of in-hospital mortality in 253 nondiabetic STEMI pa-
tients submitted to PCI. In our series, insulin resistance, as assessed by
HOMA index, was quite common, as it affected half of the population,
and was associated with a larger infarct size (as inferred by higher
values of cardiac enzymes) and more severe metabolic derangements
(as indicated by N-terminal-proBNP and lactic acid levels) [10]. In a
small cohort of 79 STEMI patients [26], patients in Killip classes II–IV
(32 patients) showed higher values of C-peptide and intensive insulinTable 3
Correlations (Spearman's Rho).
C-peptide Insulin Adm. glucose
C-peptide – 0.57, p b 0.001 0.27, p b 0.001
Insulin 0.57, p b 0.001 – 0.26, p b 0.001
Glycemia 0.27, p b 0.001 0.26, p b 0.001 –
Age −0.09, p = 0.011 −0.07, p = 0.073 0.22, p b 0.001
BMI 0.23, p b 0.001 0.28, p b 0.001 0.05, p = 0.141
LVEF −0.16, p b 0.001 −0.10, p = 0.018 −0.21, p b 0.001
Peak Tn I 0.17, p b 0.001 0.16, p b 0.001 0.18, p b 0.001
Creatinine 0.41, p b 0.001 0.11, p = 0.009 0.17, p b 0.001
Leukocytes 0.15, p b 0.001 0.20, p b 0.001 0.26, p b 0.001
Hb A1c 0.09, p = 0.027 0.14, p b 0.001 0.27, p b 0.001
BMI: body mass index, LVEF: left ventricular ejection fraction; and Tn I: troponin I.resistance (as inferred by QUICKI index [20]) in respect to patients in
Killip I and controls, respectively.
In the present investigation, we addressed, for the ﬁrst time, the
“acute insulin-resistance phenomenon” in the early phase of STEMI in a
broader way, by evaluating beta-cell secretion (by means of C-peptide)
and function (by means of HOMA-%B index) and insulin action (as indi-
cated by HOMA index).Model 1
Age (1 year step) 1.05 1.00–1.10 0.034
Peak Tn I (10 ng/ml step) 1.04 1.02–1.06 b0.001
Adm. glucose (1 g/dl step) 5.42 2.84–10.35 b0.001
Creatinine (1 mg/dl step) 1.48 0.78–2.81 0.236
Model 2
Age (1 year step) 1.05 1.00–1.10 0.037
Peak Tn I (10 ng/ml step) 1.04 1.02–1.06 b0.001
Adm. glucose (1 g/dl step) 5.40 2.77–10.53 b0.001
Adm. creatinine (1 mg/dl step) 1.47 0.77–2.82 0.240
C-peptide (1 mU/l step) 1.00 0.86–1.18 0.966
Model 3
Age (1 year step) 1.04 0.99–1.08 0.121
Peak Tn I (10 ng/ml step) 1.05 1.03–1.07 b0.001
Insulin (1 mU/l step) 1.00 0.99–1.01 0.998
Creatinine (1 mg/dl step) 1.65 1.03–2.65 0.038
C-peptide (1 mU/l step) 1.02 0.94–1.11 0.557
Hosmer–Lemeshow goodness-of-ﬁt test χ2 5.1, p = 0.742; and Nagelkerke pseudo-R2
0.30.
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signiﬁcantly higher in advanced Killip class) thus indicating an intense
stimulation of Beta-cell secretion in conditions of hemodynamic impair-
ment which are further characterized by a high degree of insulin resis-
tance (as indicated by higher values of HOMA index and log-HOMA)
and a reduced beta-cell function (as inferred by reduced values of
HOMA-%B index). Our ﬁndings can be strictly related to the acute stress
response since no difference was observed in glycated hemoglobin
between the two Killip class subgroups.
In our investigation, we further conﬁrm that acute glucose metabo-
lism is affected by age in the early phase of STEMI, since glucose, insulin
and C-peptide values were inversely related to age [28].
According to our data, the development of acute insulin resistance in
the early phase of STEMI can be viewed as an adaptive mechanism to
stress (represented by acute myocardial injury) which is similar to
other acute critical conditions (such as trauma, post surgery state, med-
ical critical illness) [29] and which is related to the severity of stress
(that is to the hemodynamic impairment). The ﬁnding that C-peptide
and insulin values cannot be related to in-ICCU death is in agreement
with the concept that they are part of an adaptive mechanism.
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